Complex disease
Complex diseases like cancer, autoimmune diseases, diabetes and heart disease involve many different genes, lifestyle choices and environmental factors, and as a result they are difficult diseases to predict, treat or manage. A primary goal of modern medical science is to extend our knowledge of the human genome to the understanding of complex diseases, how our genes in combination with environmental cues lead to such diseases and, as a result, new ways to treat them.
Personalized medicine
Personalized medicine based on genetics is a relatively new concept that has already begun to influence healthcare decision making. Individual genetic tests that predict the effectiveness or toxicity of certain drugs already exist; these tests spare lives and reduce the unnecessary suffering and financial burden caused by treatments that, while highly beneficial to some, are of no benefit to others. Oncologists already have genetic tools available to them to predict the severity of certain cancers and they can use this information guide decisions about therapeutic intervention.
Dynemo’s advantage
Dynemo provides data analysis services for personalized medicine. Our proprietary algorithms use network biology to predict the severity of a disease and drug-effectiveness prior to treatment. The use of network biology allows for a greater understanding of all the pathways and processes that are affected by disease, this greater understanding results in significantly improved predictive accuracy over existing genetic tests. Through partnerships with CLIA certified reference labs, Dynemo facilitates the diagnostic process from sample collection to final results.
Complex diseases like cancer, autoimmune diseases, diabetes and heart disease involve many different genes, lifestyle choices and environmental factors, and as a result they are difficult diseases to predict, treat or manage. A primary goal of modern medical science is to extend our knowledge of the human genome to the understanding of complex diseases, how our genes in combination with environmental cues lead to such diseases and, as a result, new ways to treat them.
Personalized medicine
Personalized medicine based on genetics is a relatively new concept that has already begun to influence healthcare decision making. Individual genetic tests that predict the effectiveness or toxicity of certain drugs already exist; these tests spare lives and reduce the unnecessary suffering and financial burden caused by treatments that, while highly beneficial to some, are of no benefit to others. Oncologists already have genetic tools available to them to predict the severity of certain cancers and they can use this information guide decisions about therapeutic intervention.
Dynemo’s advantage
Dynemo provides data analysis services for personalized medicine. Our proprietary algorithms use network biology to predict the severity of a disease and drug-effectiveness prior to treatment. The use of network biology allows for a greater understanding of all the pathways and processes that are affected by disease, this greater understanding results in significantly improved predictive accuracy over existing genetic tests. Through partnerships with CLIA certified reference labs, Dynemo facilitates the diagnostic process from sample collection to final results.